Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy

References

• Brunetti J, Pillozzi S, Falciani C, et al. (2015). Tumor-selective peptide-carrier delivery of paclitaxel increases in vivo activity of the drug. Sci Rep 5:17736.
   PubMed Web of Science ®Google Scholar
• Carlson DJ, Yenice KM, Orton CG. (2011). Tumor hypoxia is an important mechanism of radioresistance in hypofractionated radiotherapy and must be considered in the treatment planning process. Med Phys 38:6347–50.
   PubMed Web of Science ®Google Scholar
• Chan JM, Zhang L, Yuet KP, et al. (2009). PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30:1627–34.
   PubMed Web of Science ®Google Scholar
• Chang SM, Theodosopoulos P, Lamborn K, et al. (2004). Temozolomide in the treatment of recurrent malignant glioma. Cancer 100:605–11.
   PubMed Web of Science ®Google Scholar
• Chan JM, Rhee JW, Drum CL, et al. (2011). In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci USA 108:19347–52.
   PubMed Web of Science ®Google Scholar
• Cyb AF, Chmelevskaja ZI, Kudrjavceva GT. (1985). Clinical experiences with the use of metronidazole in the radiotherapy of cancer patients. Radiobiol Radiother 26:339–42.
   PubMedGoogle Scholar
• Edwards DI. (1993). Nitroimidazole drugs–action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31:9–20.
   PubMed Web of Science ®Google Scholar
• Eyre HJ, Ohlsen JD, Frank J, et al. (1984). Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neuro-Oncol 2:325–30.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Kerby T, Calvert H. (2000). Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585–97.
   PubMed Web of Science ®Google Scholar
• Frytak S, Moertel CH, Childs DS. (1978). Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 88:361–2.
   PubMed Web of Science ®Google Scholar
• Gondi V, Mehta MP. (2015). Dose escalation for GBM in the temozolamide era: in regard to Badiyan et al. Int J Radiat Oncol Biol Phys 91:453–4.
   PubMed Web of Science ®Google Scholar
• Irwin C, Hunn M, Purdie G, Hamilton D. (2007). Delay in radiotherapy shortens survival in patients with high grade glioma. J Neuro-Oncol 85:339–43.
   PubMed Web of Science ®Google Scholar
• Kinner A, Wu W, Staudt C, Iliakis G. (2008). Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36:5678–94.
   PubMed Web of Science ®Google Scholar
• Komotar RJ, Otten ML, Moise G, Connolly ES. (2008). Jr. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma-a critical review. Clin Med Oncol 2:421–2.
   PubMedGoogle Scholar
• Kunjachan S, Detappe A, Kumar R, et al. (2015). Nanoparticle mediated tumor vascular disruption: a novel strategy in radiation therapy. Nano Lett 15:7488–96.
   PubMed Web of Science ®Google Scholar
• Lee SH, Mok H, Lee Y, Park TG. (2011). Self-assembled siRNA-PLGA conjugate micelles for gene silencing. J Control Release 152:152–8.
   PubMed Web of Science ®Google Scholar
• Lee JH, Jung TY, Jung S, et al. (2013). Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. J Clin Neurosci 20:503–8.
   PubMed Web of Science ®Google Scholar
• Li Y, Baiyang L, Leran B, et al. (2017). Reduction-responsive PEtOz-SS-PCL micelle with tailored size to overcome blood-brain barrier and enhance doxorubicin antiglioma effect. Drug Deliv 24:1782–90.
   PubMed Web of Science ®Google Scholar
• Liu R, Colby AH, Gilmore D, et al. (2016). Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. Biomaterials 102:175–86.
   PubMed Web of Science ®Google Scholar
• Liu H, Li Y, Mozhi A, et al. (2014). SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment. Biomaterials 35:6519–33.
   PubMed Web of Science ®Google Scholar
• Liu HM, Zhang YF, Xie YD, et al. (2017). Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy. Int J Nanomed 12:1065–83.
   PubMed Web of Science ®Google Scholar
• Mariotti LG, Pirovano G, Savage KI, et al. (2013). Use of the gamma-H2AX assay to investigate DNA repair dynamics following multiple radiation exposures. PLoS One 8:e79541.
   PubMed Web of Science ®Google Scholar
• Mason WP, Cairncross JG. (2005). Drug Insight: temozolomide as a treatment for malignant glioma–impact of a recent trial. Nat Rev Neurol 1:88–95.
   Web of Science ®Google Scholar
• Minniti G, De Sanctis V, Muni R, et al. (2008). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97–103.
   PubMed Web of Science ®Google Scholar
• Minniti G, Lanzetta G, Scaringi C, et al. (2012). Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83:93–9.
   PubMed Web of Science ®Google Scholar
• Saleem A, Brown GD, Brady F, et al. (2003). Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63:2409–15.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96.
   PubMed Web of Science ®Google Scholar
• Stylianopoulos T. (2013). EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv 4:421–3.
   PubMedGoogle Scholar
• Sukhdeo K, Hambardzumyan D, Rich JN. (2011). Glioma development: where did it all go wrong?. Cell 146:187–8.
   PubMed Web of Science ®Google Scholar
• Thoms J, Bristow RG. (2010). DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 20:217–22.
   PubMed Web of Science ®Google Scholar
• Urtasun R, Band P, Chapman JD, et al. (1976). Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med 294:1364–7.
   PubMed Web of Science ®Google Scholar
• Urtasun RC, Miller JD, Frunchak V, et al. (1977). Radiotherapy pilot trials with sensitizers of hypoxic cells: metronidazole in supratentorial glioblastomas. Br J Radiol 50:602–3.
   PubMed Web of Science ®Google Scholar
• Urtasun RC, Sturmwind J, Rabin H, et al. (1974). Letter: “High-dose” metronidazole: a preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials. Br J Radiol 47:297–9.
   PubMed Web of Science ®Google Scholar
• Villano JL, Letarte N, Yu JM, et al. (2012). Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol 69:107–13.
   PubMed Web of Science ®Google Scholar
• Voronina SS, Pelevina II. (1977). Increasing the effectiveness of tumor radiotherapy with metronidazole. Med Radiol (Mosk) 22:37–43.
   PubMedGoogle Scholar
• Yao H, Qiu H, Shao Z, et al. (2016). Nanoparticle formulation of small DNA molecules, Dbait, improves the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomed nanotechnol Biol Med 12:2261–71.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chan JM, Gu FX, et al. (2008). Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696–702.
   PubMed Web of Science ®Google Scholar
• Zhang J, He Y, Shen X, et al. (2016). gamma-H2AX responds to DNA damage induced by long-term exposure to combined low-dose-rate neutron and gamma-ray radiation. Mutat Res Genet Toxicol Environmen Mutagen 795:36–40.
   PubMed Web of Science ®Google Scholar
• Zhou J, Schmid T, Schnitzer S, Brüne B. (2006). Tumor hypoxia and cancer progression. Cancer Lett 237:10–21.
   PubMed Web of Science ®Google Scholar